Unknown

Dataset Information

0

LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer.


ABSTRACT: Cyclin D1 is one of the most important oncoproteins that drives cancer cell proliferation and associates with tamoxifen resistance in breast cancer. Here, we identify a lncRNA, DILA1, which interacts with Cyclin D1 and is overexpressed in tamoxifen-resistant breast cancer cells. Mechanistically, DILA1 inhibits the phosphorylation of Cyclin D1 at Thr286 by directly interacting with Thr286 and blocking its subsequent degradation, leading to overexpressed Cyclin D1 protein in breast cancer. Knocking down DILA1 decreases Cyclin D1 protein expression, inhibits cancer cell growth and restores tamoxifen sensitivity both in vitro and in vivo. High expression of DILA1 is associated with overexpressed Cyclin D1 protein and poor prognosis in breast cancer patients who received tamoxifen treatment. This study shows the previously unappreciated importance of post-translational dysregulation of Cyclin D1 contributing to tamoxifen resistance in breast cancer. Moreover, it reveals the novel mechanism of DILA1 in regulating Cyclin D1 protein stability and suggests DILA1 is a specific therapeutic target to downregulate Cyclin D1 protein and reverse tamoxifen resistance in treating breast cancer.

SUBMITTER: Shi Q 

PROVIDER: S-EPMC7608661 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer.

Shi Qianfeng Q   Li Yudong Y   Li Shunying S   Jin Liang L   Lai Hongna H   Wu Yanqing Y   Cai Zijie Z   Zhu Mengdi M   Li Qian Q   Li Ying Y   Wang Jingru J   Liu Yujie Y   Wu Zongqi Z   Song Erwei E   Liu Qiang Q  

Nature communications 20201102 1


Cyclin D1 is one of the most important oncoproteins that drives cancer cell proliferation and associates with tamoxifen resistance in breast cancer. Here, we identify a lncRNA, DILA1, which interacts with Cyclin D1 and is overexpressed in tamoxifen-resistant breast cancer cells. Mechanistically, DILA1 inhibits the phosphorylation of Cyclin D1 at Thr286 by directly interacting with Thr286 and blocking its subsequent degradation, leading to overexpressed Cyclin D1 protein in breast cancer. Knockin  ...[more]

Similar Datasets

| S-EPMC7940940 | biostudies-literature
| S-EPMC4791209 | biostudies-literature
| S-EPMC2409465 | biostudies-other
| S-EPMC3192789 | biostudies-literature
| S-EPMC2856324 | biostudies-literature
| S-EPMC10641764 | biostudies-literature
| S-EPMC4756695 | biostudies-literature
| S-ECPF-GEOD-27260 | biostudies-other
| S-EPMC9912664 | biostudies-literature
| S-EPMC7150441 | biostudies-literature